Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
- 29 January 2025 - 1 mins read
The purpose of the protocol is to determine safety, tolerability, recommended dose (RD), pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of IPN60090 as a single agent (Part A) and in combination with pembrolizumab (Part B) or paclitaxel (Part C) in patients with advanced solid tumours and to evaluate food effect (Part D).
29 January 2025
1 mins read
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot...
29 January 2025
1 mins read
Study to Assess the Efficacy and Safety of Dysport® in the Treatment of Chronic Plantar Fasciitis
29 January 2025
1 mins read
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
29 January 2025
1 mins read
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
29 January 2025
1 mins read
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
29 January 2025
1 mins read
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
29 January 2025
1 mins read
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
29 January 2025
1 mins read
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
29 January 2025
1 mins read
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
29 January 2025
1 mins read